FDA approves Novo Nordisk's injection for obesity

December 23, 2014 10:16 PM

13 0

(Reuters) - The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans.

The injectable drug, to be marketed as Saxenda, is the second obesity treatment to be approved this year after Orexigen Therapeutics Inc's oral medication Contrave in September.

Read more

To category page